STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Acquires 8,221 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 8,221 shares of the business’s stock in a transaction dated Thursday, January 16th. The shares were bought at an average price of $21.50 per share, with a total value of $176,751.50. Following the purchase, the insider now directly owns 10,878,007 shares of the company’s stock, valued at approximately $233,877,150.50. The trade was a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, January 14th, Broadwood Partners, L.P. acquired 21,155 shares of STAAR Surgical stock. The stock was purchased at an average cost of $21.46 per share, for a total transaction of $453,986.30.
• On Wednesday, December 18th, Broadwood Partners, L.P. bought 23,000 shares of STAAR Surgical stock. The stock was purchased at an average price of $24.33 per share, with a total value of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. purchased 53,500 shares of STAAR Surgical stock. The shares were purchased at an average price of $24.24 per share, for a total transaction of $1,296,840.00.

STAAR Surgical Price Performance

Shares of NASDAQ:STAA opened at $22.29 on Friday. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of 50.66 and a beta of 0.63. The business’s 50 day simple moving average is $25.38 and its 200-day simple moving average is $31.92. STAAR Surgical has a 12 month low of $21.13 and a 12 month high of $52.68.

Institutional Trading of STAAR Surgical

A number of institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its stake in shares of STAAR Surgical by 25.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 459,655 shares of the medical instruments supplier’s stock worth $21,884,000 after buying an additional 94,422 shares during the last quarter. Renaissance Technologies LLC raised its position in STAAR Surgical by 137.5% during the second quarter. Renaissance Technologies LLC now owns 68,400 shares of the medical instruments supplier’s stock worth $3,257,000 after acquiring an additional 39,600 shares during the last quarter. Edgestream Partners L.P. purchased a new stake in shares of STAAR Surgical in the second quarter valued at about $390,000. Mutual of America Capital Management LLC lifted its holdings in shares of STAAR Surgical by 214.7% in the second quarter. Mutual of America Capital Management LLC now owns 26,459 shares of the medical instruments supplier’s stock valued at $1,260,000 after purchasing an additional 18,051 shares in the last quarter. Finally, Hsbc Holdings PLC grew its position in shares of STAAR Surgical by 12.4% in the second quarter. Hsbc Holdings PLC now owns 10,290 shares of the medical instruments supplier’s stock valued at $492,000 after purchasing an additional 1,137 shares during the last quarter. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Stephens raised STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. Canaccord Genuity Group reduced their price target on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a report on Monday, December 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $42.83.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.